



Chronic Malignancies Working Party

CML & MDS & PH-neg MPN

Activities of the working party and subcommittees


Chair: Ibrahim Yakoub-Agha

Secretary: Patrick Hayden

E-mail address: cmwpebmt@lumc.nl

Subcommittee Chronic Myeloid Leukemia (CML)

Chair: Yves Chalandon



Data Quality Initiative

Fifty-four centers, comprising 641 patients, have participated in CML Data Quality Initiative. The data will be utilized for various studies in the future.

Studies starting soon

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic HSCT

Hugues de Lavallade

Outcome Unrelated CB transplantation in patients with CML

Hugues de Lavallade

Prognostic value of additional cytogenetic abnormalities at transplantation in CML patients


Jo Caers

Post-Transplant Scoring System for CML Based on Retrospective Analysis of Patients Surviving more than 100 Days after Allo-HSCT

Maria Mappoura & Yves Chalandon

Subcommittee Myelodysplastic Syndromes (MDS)

Chair: Marie Robin, Vice-chair: Christof Scheid, CMML: Francesco Onida



Presentations at EBMT 2021

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer

Mitja Nabergoj et al.

Therapy-related myeloid neoplasms (t-MNs) represent a clinical dilemma in the transplantation field. In this retrospective registry study, we try to add new insights in this field considering the relevance of t-MN, focusing on t-MN secondary to breast cancer treatment.


Retrospective Analysis evaluating the effect of age on outcomes after allogeneic hematopoietic cell transplantation in Chronic Myelomonocytic Leukemia: A study of the EBMT-CMWP

Alicia Rovio et al.

Despite there being no consensus on the optimal therapy for CMML, it is generally recognized that allo-HCT is the only curative treatment modality. Nonetheless, CMML patient survival outcomes after allo-HCT are weakened by high non-relapse mortality (NRM) and relapse rates. In this retrospective study we aimed to investigate factors associated with allo-HCT outcomes, primarily focusing on age.

Subcommittee PH-Neg Myeloproliferative Neoplasms (MPN)

Chair: Donal McLornan, Vice-chair: Juan Carlos Hernández-Boluda, Tomasz Czerw



Active data requests

We have several ongoing data requests at the moment:

Post-Transplant Cyclophosphamide as GvHD prophylaxis for Allogeneic HSCT for MF as compared to standard GvHD prophylaxis

Yves Chalandon

Treosulfan vs Busulfan in conditioning regimen before allogeneic transplantation in Myelofibrosis patients: a CMWP Study

Marie Robin

Impact of splenic irradiation in patients with Myelofibrosis undergoing allogeneic-SCT

Nico Gagelmann & Nicolaus Kröger

Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Eosinophilic Disorders: A Retrospective Study by the Chronic Malignancies Working Party of EBMT

Donal McLornan

If you are interested in participating or you want more information, please contact us at:

cmwpebmt@lumc.nl

Chronic Malignancies Working Party Session EBMT 2021

1. Scientific activity of the CMWP

Ibrahim Yakoub-Agha

2. Who and when in the course of disease to transplant? – Myelodysplastic syndromes

Ghulam Mufti

3. Who and when in the course of disease to transplant? – Myelofibrosis

Donal McLornan

4. Is Chronic Myeloid Leukaemia still an indication for allo-HCT?

Yves Chalandon

5. Is Chronic Lymphocytic Leukemia still an indication for allo-HCT?

Peter Dreger

Available On-Demand